lenalidomide has been researched along with Thrombocythemia in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gangat, N; Mudireddy, M; Nicolosi, M; Patnaik, MM; Tefferi, A; Vallapureddy, R | 1 |
| Beguin, Y; Caberg, JH; Caers, J; Hafraoui, K; Keutgens, A; Lambert, F; Tassin, F | 1 |
| Patnaik, MM; Tefferi, A | 1 |
| de Wolf, JT; Huls, G; Mulder, AB; Rosati, S; van de Loosdrecht, AA; Vellenga, E | 1 |
| Chmarzyńska, E; Dwilewicz-Trojaczek, J; Jędrzejczak, WW; Koperski, Ł; Pastwińska, A; Paszkowska-Kowalewska, M; Ziarkiewicz, M; Ziarkiewicz-Wróblewska, B | 1 |
| Abkowitz, JL; Keel, SB; Kirn-Safran, CB; O'Leary, MN; Phelps, S; Sabo, KM | 1 |
| He, Y; Li, W; Li, X; Liu, F; Liu, X; You, Y; Zhang, M; Zheng, J; Zou, P | 1 |
1 review(s) available for lenalidomide and Thrombocythemia
| Article | Year |
|---|---|
Refractory anemia with ring sideroblasts and RARS with thrombocytosis.
Topics: Anemia, Refractory; Anemia, Sideroblastic; Angiogenesis Inhibitors; Aspirin; Female; Humans; Iron Overload; Janus Kinase 2; Lenalidomide; Male; Mutation; Myelodysplastic Syndromes; Phosphoproteins; Platelet Aggregation Inhibitors; Receptors, Thrombopoietin; Ribonucleoprotein, U2 Small Nuclear; Risk Factors; RNA Splicing Factors; Thalidomide; Thrombocytosis | 2015 |
6 other study(ies) available for lenalidomide and Thrombocythemia
| Article | Year |
|---|---|
Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
Topics: Anemia, Sideroblastic; Humans; Lenalidomide; Myelodysplastic-Myeloproliferative Diseases; Thrombocytosis | 2018 |
Haematological and molecular responses in refractory anaemia with ring sideroblasts and thrombocytosis treated with lenalidomide.
Topics: Aged, 80 and over; Anemia, Refractory; Bone Marrow; Erythrocytes, Abnormal; Female; Humans; Immunologic Factors; Lenalidomide; Thalidomide; Thrombocytosis; Treatment Outcome | 2014 |
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.
Topics: Aged, 80 and over; Anabolic Agents; Anemia, Refractory; Anemia, Sideroblastic; Antineoplastic Agents; Erythropoietin; Humans; Hypertension, Pulmonary; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Mutation; Pulmonary Embolism; Pyridoxine; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Thrombocytosis; Vitamin B Complex | 2010 |
Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) with superimposed 5q-syndrome.
Topics: Aged; Anemia, Macrocytic; Anemia, Refractory; Anemia, Sideroblastic; Antineoplastic Agents; Bone Marrow Cells; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Therapy, Combination; Humans; Hydroxyurea; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Thalidomide; Thrombocytosis | 2010 |
Establishing Rps6 hemizygous mice as a model for studying how ribosomal protein haploinsufficiency impairs erythropoiesis.
Topics: Agranulocytosis; Alleles; Anemia, Diamond-Blackfan; Anemia, Macrocytic; Animals; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Models, Animal; Erythrocyte Indices; Erythropoiesis; Gene Expression Regulation, Developmental; Hemoglobins; Heterozygote; Lenalidomide; Lymphopenia; Mice; Mice, Inbred C57BL; Prednisone; Ribosomal Protein S6; Ribosomal Proteins; Ribosomes; RNA-Binding Proteins; Thalidomide; Thrombocytosis | 2012 |
Response to lenalidomide of a patient with t(2;3)(p23;q29) and JAK2 non-mutated refractory anemia with ring sideroblasts and thrombocytosis.
Topics: Adult; Anemia, Refractory; Bone Marrow; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 3; Female; Humans; Janus Kinase 2; Karyotype; Lenalidomide; Thalidomide; Thrombocytosis; Translocation, Genetic; Treatment Outcome | 2013 |